CLU and neoplasm: To further confirm the efficiency of targeted therapy against CLU pathway for treatment of TNBC, we generated patient‐derived TNBC organoid assays (Figure 7J–L) and patient‐derived xenograft (PDX) TNBC tumor murine models (Figure 7M–Q).